Biomea Fusion, Inc.
NASDAQ:BMEABiotechnology
-$0.03 today
- Market cap
- $53.18M
- Beta
- -0.33
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$0.62
Volume 3.50M
Average 1.52M
BMEA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Biomea Fusion, Inc.NASDAQ: BMEA
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 24.6% from a year ago
Cash & equivalents stood at $44.69M at the end of Q1 FY2026, up 24.6% from a year earlier and down 19.9% from the prior quarter. Over 3 fiscal years it compounded at -20.7% a year.
Context
- Cash & equivalents amounted to 96.4% of total assets at the end of Q1 FY2026, up 31.2 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +24.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 55.81M USD
- Year-over-year change
- -4.2%
- 4-year CAGR
- -21.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 55.81M | -4.2% |
| FY2024 | 2024-12-31 | 58.28M | -67.0% |
| FY2023 | 2023-12-31 | 176.87M | +58.1% |
| FY2022 | 2022-12-31 | 111.9M | -23.2% |
| FY2021 | 2021-12-31 | 145.74M | — |
Cash & Equivalents vs competitors
How BMEA compares with its peers on the latest reported figures
- BMEA's Mar 2026 cash & equivalents of $44.69M is the 5th highest of the 9 companies compared; the peer median is $51.15M.
- Its year-over-year change of +24.6% is the 7th highest of 9, against a peer median of +53.3%.
- Cash & equivalents amounts to 96.4% of total assets for BMEA, versus a peer median of 49.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $186.63M | +1204.7% | -47.5% | 98.4% | |
| Mar 2026 | $99.21M | +101.1% | — | 94.1% | |
| Mar 2026 | $73.68M | -30.6% | +7.1% | 30.4% | |
| Mar 2026 | $63.17M | +50.0% | +18.3% | 63.6% | |
| Mar 2026 | $44.69M | +24.6% | -20.7% | 96.4% | |
| Mar 2026 | $39.13M | -23.8% | -29.5% | 40.5% | |
| Mar 2026 | $37.37M | +89.0% | +300.4% | 58.0% | |
| Mar 2026 | $32.28M | +56.6% | -30.5% | 18.1% | |
CBUSCibus, Inc. | Mar 2026 | $30.33M | +28.6% | +42.5% | 9.4% |
| Peer median (excluding BMEA) | $51.15M | +53.3% | +7.1% | 49.3% | |
Competitors are the stored peer set for BMEA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 145.74M | 111.9M | 176.87M | 58.28M | 55.81M |
| Short-term Investments | 27.78M | 1.15M | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 4.77M | 2.32M | 10.05M | 2.24M |
| Total Current Assets | 176.56M | 117.82M | 179.18M | 68.33M | 58.05M |
| Property, Plant & Equipment (Net) | 5.69M | 7.99M | 14.87M | 10.62M | 153K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 1.88M | 0 | 0 | 0 | 369K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.58M | 3.5M | 5.87M | 988K | 0 |
| Total Non-current Assets | 9.14M | 11.49M | 20.75M | 11.61M | 522K |
| Total Assets | 185.71M | 129.31M | 199.93M | 79.94M | 58.57M |
| Account Payables | 1.33M | 6.83M | 6.85M | 12.93M | 3.23M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 480K | 636K | 192K | 203K | 169K |
| Total Current Liabilities | 4.64M | 19.1M | 22.86M | 21.67M | 11.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 17.79M |
| Total Non-current Liabilities | 2.29M | 1.67M | 7.83M | 6.69M | 17.92M |
| Total Liabilities | 6.92M | 20.77M | 30.69M | 28.37M | 29.02M |
| Common Stock | 3K | 3K | 4K | 4K | 7K |
| Retained Earnings | (49.74M) | (131.57M) | (248.83M) | (387.25M) | (449.05M) |
| Accumulated OCI | (10K) | (1K) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 178.78M | 108.54M | 169.24M | 51.57M | 29.55M |
| Total Debt | 2.85M | 2.29M | 10.3M | 8.77M | 1.59M |
| Net Debt | (142.89M) | (109.61M) | (166.57M) | (49.51M) | (54.22M) |
Biomea Fusion, Inc.
NASDAQ:BMEA
Intrinsic Alpha fair value
Locked
Current Price
$0.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.